Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.

Diabetes Metab Syndr Obes · 2014 · PMC4085306 · PMID 25061325

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

did not reach statistical significanceP =0.20not close (p > 0.1)

Orlistat tended to decrease body weight over the study period compared to vehicle-treated controls, although this effect did not reach statistical significance ( P =0.20, Figure 2A ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.